Bortezomib ocular toxicities: Outcomes with ketotifen
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2019-03, Vol.94 (3), p.E80-E82 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E82 |
|---|---|
| container_issue | 3 |
| container_start_page | E80 |
| container_title | American journal of hematology |
| container_volume | 94 |
| creator | Dennis, Michael Maoz, Asaf Hughes, David Sanchorawala, Vaishali Sloan, J. Mark Sarosiek, Shayna |
| description | |
| doi_str_mv | 10.1002/ajh.25382 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2174272156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2174272156</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3882-1c431de8320c9613b4dfc48c7c49bb0caf89df6433675806da164271891089b93</originalsourceid><addsrcrecordid>eNp1kLFOwzAURS0EoqUw8AMoEhND2mc7cWy2UgEFVeoCs5U4jurQ1MV2VMrXE0hhY3pvODpXOghdYhhjADLJ69WYpJSTIzTEIFjMWUqO0RAow90PYoDOvK8BME44nKIBhTRLQfAhSu-sC_rTNqaIrGrXuYuC_TDKBKP9bbRsg7KN9tHOhFX0poMNptKbc3RS5WuvLw53hF4f7l9m83ixfHyaTRexopyTGKuE4lJzSkAJhmmRlJVKuMpUIooCVF5xUVYsoZRlKQdW5pglJMNcYOCiEHSErnvv1tn3Vvsga9u6TTcpCc46lOCUddRNTylnvXe6kltnmtztJQb5HUh2geRPoI69OhjbotHlH_lbpAMmPbAza73_3ySnz_Ne-QVD3m16</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2174272156</pqid></control><display><type>article</type><title>Bortezomib ocular toxicities: Outcomes with ketotifen</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Dennis, Michael ; Maoz, Asaf ; Hughes, David ; Sanchorawala, Vaishali ; Sloan, J. Mark ; Sarosiek, Shayna</creator><creatorcontrib>Dennis, Michael ; Maoz, Asaf ; Hughes, David ; Sanchorawala, Vaishali ; Sloan, J. Mark ; Sarosiek, Shayna</creatorcontrib><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.25382</identifier><identifier>PMID: 30575098</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Amyloidosis - drug therapy ; Amyloidosis - pathology ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Bortezomib ; Bortezomib - administration & dosage ; Bortezomib - adverse effects ; Chalazion - chemically induced ; Chalazion - drug therapy ; Chalazion - physiopathology ; Conjunctivitis - chemically induced ; Conjunctivitis - drug therapy ; Conjunctivitis - physiopathology ; Female ; Hematology ; Histamine H1 Antagonists - therapeutic use ; Humans ; Inhibitor drugs ; Ketotifen - therapeutic use ; Male ; Middle Aged ; Multiple Myeloma - drug therapy ; Multiple Myeloma - pathology ; Ophthalmic Solutions - therapeutic use ; Retrospective Studies ; Treatment Outcome</subject><ispartof>American journal of hematology, 2019-03, Vol.94 (3), p.E80-E82</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3882-1c431de8320c9613b4dfc48c7c49bb0caf89df6433675806da164271891089b93</citedby><cites>FETCH-LOGICAL-c3882-1c431de8320c9613b4dfc48c7c49bb0caf89df6433675806da164271891089b93</cites><orcidid>0000-0002-0075-6735 ; 0000-0002-6307-2445 ; 0000-0002-7502-3923</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.25382$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.25382$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30575098$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dennis, Michael</creatorcontrib><creatorcontrib>Maoz, Asaf</creatorcontrib><creatorcontrib>Hughes, David</creatorcontrib><creatorcontrib>Sanchorawala, Vaishali</creatorcontrib><creatorcontrib>Sloan, J. Mark</creatorcontrib><creatorcontrib>Sarosiek, Shayna</creatorcontrib><title>Bortezomib ocular toxicities: Outcomes with ketotifen</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><subject>Adult</subject><subject>Aged</subject><subject>Amyloidosis - drug therapy</subject><subject>Amyloidosis - pathology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Bortezomib</subject><subject>Bortezomib - administration & dosage</subject><subject>Bortezomib - adverse effects</subject><subject>Chalazion - chemically induced</subject><subject>Chalazion - drug therapy</subject><subject>Chalazion - physiopathology</subject><subject>Conjunctivitis - chemically induced</subject><subject>Conjunctivitis - drug therapy</subject><subject>Conjunctivitis - physiopathology</subject><subject>Female</subject><subject>Hematology</subject><subject>Histamine H1 Antagonists - therapeutic use</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Ketotifen - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - pathology</subject><subject>Ophthalmic Solutions - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kLFOwzAURS0EoqUw8AMoEhND2mc7cWy2UgEFVeoCs5U4jurQ1MV2VMrXE0hhY3pvODpXOghdYhhjADLJ69WYpJSTIzTEIFjMWUqO0RAow90PYoDOvK8BME44nKIBhTRLQfAhSu-sC_rTNqaIrGrXuYuC_TDKBKP9bbRsg7KN9tHOhFX0poMNptKbc3RS5WuvLw53hF4f7l9m83ixfHyaTRexopyTGKuE4lJzSkAJhmmRlJVKuMpUIooCVF5xUVYsoZRlKQdW5pglJMNcYOCiEHSErnvv1tn3Vvsga9u6TTcpCc46lOCUddRNTylnvXe6kltnmtztJQb5HUh2geRPoI69OhjbotHlH_lbpAMmPbAza73_3ySnz_Ne-QVD3m16</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Dennis, Michael</creator><creator>Maoz, Asaf</creator><creator>Hughes, David</creator><creator>Sanchorawala, Vaishali</creator><creator>Sloan, J. Mark</creator><creator>Sarosiek, Shayna</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-0075-6735</orcidid><orcidid>https://orcid.org/0000-0002-6307-2445</orcidid><orcidid>https://orcid.org/0000-0002-7502-3923</orcidid></search><sort><creationdate>201903</creationdate><title>Bortezomib ocular toxicities: Outcomes with ketotifen</title><author>Dennis, Michael ; Maoz, Asaf ; Hughes, David ; Sanchorawala, Vaishali ; Sloan, J. Mark ; Sarosiek, Shayna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3882-1c431de8320c9613b4dfc48c7c49bb0caf89df6433675806da164271891089b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Amyloidosis - drug therapy</topic><topic>Amyloidosis - pathology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Bortezomib</topic><topic>Bortezomib - administration & dosage</topic><topic>Bortezomib - adverse effects</topic><topic>Chalazion - chemically induced</topic><topic>Chalazion - drug therapy</topic><topic>Chalazion - physiopathology</topic><topic>Conjunctivitis - chemically induced</topic><topic>Conjunctivitis - drug therapy</topic><topic>Conjunctivitis - physiopathology</topic><topic>Female</topic><topic>Hematology</topic><topic>Histamine H1 Antagonists - therapeutic use</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Ketotifen - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - pathology</topic><topic>Ophthalmic Solutions - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dennis, Michael</creatorcontrib><creatorcontrib>Maoz, Asaf</creatorcontrib><creatorcontrib>Hughes, David</creatorcontrib><creatorcontrib>Sanchorawala, Vaishali</creatorcontrib><creatorcontrib>Sloan, J. Mark</creatorcontrib><creatorcontrib>Sarosiek, Shayna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dennis, Michael</au><au>Maoz, Asaf</au><au>Hughes, David</au><au>Sanchorawala, Vaishali</au><au>Sloan, J. Mark</au><au>Sarosiek, Shayna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bortezomib ocular toxicities: Outcomes with ketotifen</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2019-03</date><risdate>2019</risdate><volume>94</volume><issue>3</issue><spage>E80</spage><epage>E82</epage><pages>E80-E82</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>30575098</pmid><doi>10.1002/ajh.25382</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-0075-6735</orcidid><orcidid>https://orcid.org/0000-0002-6307-2445</orcidid><orcidid>https://orcid.org/0000-0002-7502-3923</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2019-03, Vol.94 (3), p.E80-E82 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_journals_2174272156 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Amyloidosis - drug therapy Amyloidosis - pathology Antineoplastic Combined Chemotherapy Protocols - adverse effects Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Chalazion - chemically induced Chalazion - drug therapy Chalazion - physiopathology Conjunctivitis - chemically induced Conjunctivitis - drug therapy Conjunctivitis - physiopathology Female Hematology Histamine H1 Antagonists - therapeutic use Humans Inhibitor drugs Ketotifen - therapeutic use Male Middle Aged Multiple Myeloma - drug therapy Multiple Myeloma - pathology Ophthalmic Solutions - therapeutic use Retrospective Studies Treatment Outcome |
| title | Bortezomib ocular toxicities: Outcomes with ketotifen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T07%3A24%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bortezomib%20ocular%20toxicities:%20Outcomes%20with%20ketotifen&rft.jtitle=American%20journal%20of%20hematology&rft.au=Dennis,%20Michael&rft.date=2019-03&rft.volume=94&rft.issue=3&rft.spage=E80&rft.epage=E82&rft.pages=E80-E82&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.25382&rft_dat=%3Cproquest_cross%3E2174272156%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2174272156&rft_id=info:pmid/30575098&rfr_iscdi=true |